Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azithromycin + dexamethasone is a fixed-dose combination of two pharmaceutical agents used primarily in the treatment of conjunctivitis and blepharoconjunctivitis. Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, thereby preventing the growth and spread of bacteria. Dexamethasone is a synthetic corticosteroid that suppresses inflammation by inhibiting chemical mediators such as prostaglandins and leukotrienes. The combination leverages both antibacterial and anti-inflammatory actions to treat infections and reduce associated ocular inflammation[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on azithromycin + dexamethasone.